Zinzino AB (publ.): Preliminary Sales Report Q3 2025
Zinzino group revenue increased 48% in Q3, compared with the previous year.
The revenue in September 2025 for Zinzino's sales markets increased by 53 % and amounted to SEK 273.5 (178.7) million. Faun Pharma's external sales decreased and amounted to SEK 3.7 (5.8) million. Overall, the Group increased revenues by 50% to SEK 277.2 (184..5) million compared with the previous year.
Revenue in Zinzino's sales markets increased by 54 % in the third quarter of 2025 compared with the same period last year and amounted to SEK 777.3 (504.4) million. Total revenues in the Group increased by 48% in the third quarter and amounted to SEK 786.7 (532.8) million.
Accumulated revenue for January – September 2025 increased by 54% to SEK 2,304.9 (1,494.3) million.
Revenues were distributed as follows:
|
Regions, mSEK |
25-Sep |
24-Sep |
Change |
Q3 2025 |
Q3 2024 |
Change |
YTD 2025 |
YTD 2024 |
Change |
|
The Nordics |
26.5 |
25.4 |
4% |
79.6 |
72.5 |
10% |
235.1 |
214.0 |
10% |
|
Central Europe |
93.8 |
48.7 |
93% |
242.8 |
138.6 |
75% |
657.9 |
394.4 |
67% |
|
East Europe |
29.4 |
28.3 |
4% |
89.7 |
88.3 |
2% |
276.2 |
279.9 |
-1% |
|
South & West Europe |
50.1 |
38.0 |
32% |
137.2 |
104.2 |
32% |
399.2 |
264.5 |
51% |
|
The Baltics |
8.9 |
7.2 |
24% |
28.6 |
21.9 |
31% |
85.3 |
69.4 |
23% |
|
North America |
41.3 |
20.3 |
103% |
129.8 |
52.6 |
147% |
382.1 |
134.0 |
185% |
|
Asia-Pacific |
21.6 |
9.6 |
125% |
63.7 |
22.3 |
186% |
212.7 |
47.5 |
348% |
|
Africa |
1.9 |
1.2 |
58% |
5.8 |
4.0 |
46% |
16.0 |
10.9 |
47% |
|
Zinzino |
273.5 |
178.7 |
53% |
777.3 |
504.4 |
54% |
2264.5 |
1414.6 |
60% |
|
Faun Pharma |
3.7 |
5.8 |
-36% |
9.4 |
28.4 |
-67% |
40.4 |
79.7 |
-49% |
|
Zinzino Group |
277.2 |
184.5 |
50% |
786.7 |
532.8 |
48% |
2304.9 |
1494.3 |
54% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: DNB Carnegie Investment Bank AB (publ.)
Zinzino is a global direct sales company from Scandinavia that specializes in test-based, personalized nutritional supplements and scientific skincare. It is a public company with shares listed on the Nasdaq First North Premier Growth Market. The company's scientifically proven dietary supplements are available in more than 100 markets worldwide. Zinzino has acquired assets in the direct sales companies Zurvita, Xelliss, Valentus, Ecosystem, Bodẽ Pro, and Truvy. The company is a partner in the Cypriot olive oil producer Cleanthi Alpha Olenic LTD. The company also owns the Swiss biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company's headquarters are located in Gothenburg, with additional offices in Europe, Asia, and Australia.